Erratum: Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)

作者：Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey E. Roeker, John M. Burke, Christine I. Chen, Norbert Grząśko, George Follows, Zoltán Mátrai, Alessandro Sanna, Lugui Qiu, Ru Feng, Vu Minh Hua, Wojciech Jurczak, Matthias Ritgen, Shuhua Yi, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Denise Y. Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M. Barr · 发表于：Journal of Clinical Oncology · 年份：2025 · DOI：10.1200/jco-25-01700 · 被引用次数：1 · 研究领域：Chronic Lymphocytic Leukemia Research、Lymphoma Diagnosis and Treatment、Chronic Myeloid Leukemia Treatments